Detalhe da pesquisa
1.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Ann Hematol
; 99(6): 1273-1281, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32193630
2.
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Nat Med
; 27(3): 491-503, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619369